Cipla Limited has allotted 585 fully paid-up equity shares under its employee stock option schemes, as announced to stock exchanges on December 17, 2025. The pharmaceutical company's Operations and Administrative Committee approved the allotment pursuant to the exercise of employee stock options and stock appreciation rights.

Share Allotment Details

The allotment comprises 585 equity shares of ₹2 each, issued under two specific schemes operated by the company. The shares were allotted following the exercise of options under both the Employee Stock Option Scheme 2013-A and the Cipla Employee Stock Appreciation Rights Scheme 2021.

Updated Share Capital Structure

Following this allotment, Cipla's share capital structure has been updated to reflect the increased equity base. The company's issued, subscribed and paid-up share capital now stands at ₹1,615.54 crores, representing a total of 80.78 crore equity shares.

Regulatory Compliance

The company has informed multiple stock exchanges about this development in compliance with Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The notification was sent to BSE Limited, National Stock Exchange of India Limited, and Societe de la Bourse de Luxembourg.

The communication was signed by Rajendra Chopra, Company Secretary, and copies were also sent to Central Depository Services (India) Limited and National Securities Depository Limited for record-keeping purposes. This allotment represents the company's ongoing commitment to its employee incentive programs through structured stock option schemes.

Cipla has announced the launch of Yurpeak (Tirzepatide), a new therapeutic treatment designed for patients suffering from obesity and Type 2 diabetes. This launch marks a significant addition to the company's pharmaceutical portfolio in the metabolic disorders segment.

Product Overview

Yurpeak contains Tirzepatide as its active pharmaceutical ingredient, targeting two major health conditions that affect millions of patients globally. The medication addresses both obesity management and Type 2 diabetes treatment, offering a dual therapeutic approach for patients dealing with these interconnected metabolic conditions.

Market Significance

The launch of Yurpeak represents Cipla's strategic focus on expanding its presence in the diabetes and obesity treatment market. This therapeutic area continues to show significant demand due to the growing prevalence of metabolic disorders worldwide. The introduction of Tirzepatide-based treatment adds to the available options for healthcare providers treating patients with these conditions.

Company Portfolio Enhancement

With the addition of Yurpeak, Cipla strengthens its position in the metabolic disorders segment. The company continues to diversify its pharmaceutical offerings, focusing on therapeutic areas with substantial patient needs. This launch demonstrates the company's commitment to bringing innovative treatment solutions to the market for managing complex health conditions like obesity and diabetes.